Vishal V. Pendharkar

10 Biopolis Road, Chromos #05-01
Singapore, 138670, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Journal: Journal of medicinal chemistry

Published: December 23, 2025

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Journal: Journal of medicinal chemistry

Published: August 07, 2025

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.

Journal: Infectious diseases and therapy

Published: June 17, 2022

Lumefantrine solid dispersions with piperine for the enhancement of solubility, bioavailability and anti-parasite activity.

Lumefantrine solid dispersions with piperine for the enhancement of solubility, bioavailability and anti-parasite activity.

Journal: International journal of pharmaceutics

Published: June 15, 2022

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: July 16, 2021

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Journal: Journal of medicinal chemistry

Published: January 08, 2020

Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3".

Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3".

Journal: ACS medicinal chemistry letters

Published: August 16, 2019

Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Journal: ACS medicinal chemistry letters

Published: April 15, 2019

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.

Journal: European journal of medicinal chemistry

Published: May 07, 2018

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 25, 2018

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Journal: Journal of medicinal chemistry

Published: April 24, 2018

Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.

Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 04, 2017

Showing 1-12 of 24

Last Updated: 09/26/2026